000169806 001__ 169806
000169806 005__ 20240229133655.0
000169806 0247_ $$2doi$$a10.1007/s00018-021-03889-5
000169806 0247_ $$2pmid$$apmid:34223911
000169806 0247_ $$2pmc$$apmc:PMC8256233
000169806 0247_ $$2ISSN$$a0014-4754
000169806 0247_ $$2ISSN$$a1420-682X
000169806 0247_ $$2ISSN$$a1420-9071
000169806 0247_ $$2altmetric$$aaltmetric:108746229
000169806 037__ $$aDKFZ-2021-01560
000169806 041__ $$aEnglish
000169806 082__ $$a610
000169806 1001_ $$00000-0002-0499-2460$$aBoutin, Sébastien$$b0
000169806 245__ $$aHost factors facilitating SARS-CoV-2 virus infection and replication in the lungs.
000169806 260__ $$aCham (ZG)$$bSpringer International Publishing AG$$c2021
000169806 3367_ $$2DRIVER$$aarticle
000169806 3367_ $$2DataCite$$aOutput Types/Journal article
000169806 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1642167369_15951$$xReview Article
000169806 3367_ $$2BibTeX$$aARTICLE
000169806 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169806 3367_ $$00$$2EndNote$$aJournal Article
000169806 500__ $$a2021 Aug;78(16):5953-5976
000169806 520__ $$aSARS-CoV-2 is the virus causing the major pandemic facing the world today. Although, SARS-CoV-2 primarily causes lung infection, a variety of symptoms have proven a systemic impact on the body. SARS-CoV-2 has spread in the community quickly infecting humans from all age, ethnicities and gender. However, fatal outcomes have been linked to specific host factors and co-morbidities such as age, hypertension, immuno-deficiencies, chronic lung diseases or metabolic disorders. A major shift in the microbiome of patients suffering of the coronavirus disease 2019 (COVID-19) have also been observed and is linked to a worst outcome of the disease. As many co-morbidities are already known to be associated with a dysbiosis of the microbiome such as hypertension, diabetes and metabolic disorders. Host factors and microbiome changes are believed to be involved as a network in the acquisition of the infection and the development of the diseases. We will review in detail in this manuscript, the immune response toward SARS-CoV-2 infection as well as the host factors involved in the facilitation and worsening of the infection. We will also address the impact of COVID-19 on the host's microbiome and secondary infection which also worsen the disease.
000169806 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000169806 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169806 650_7 $$2Other$$aCOVID-19
000169806 650_7 $$2Other$$aCo-morbidities
000169806 650_7 $$2Other$$aHost factor
000169806 650_7 $$2Other$$aInnate immune response
000169806 650_7 $$2Other$$aMicrobiome
000169806 650_7 $$2Other$$aSARS-CoV-2
000169806 7001_ $$aHildebrand, Dagmar$$b1
000169806 7001_ $$0P:(DE-He78)4658b59d5b4e54b919fc63ab1213c78f$$aBoulant, Steeve$$b2$$udkfz
000169806 7001_ $$aKreuter, Michael$$b3
000169806 7001_ $$aRüter, Jule$$b4
000169806 7001_ $$aPallerla, Srinivas Reddy$$b5
000169806 7001_ $$aVelavan, Thirumalaisamy P$$b6
000169806 7001_ $$aNurjadi, Dennis$$b7
000169806 773__ $$0PERI:(DE-600)1458497-9$$a10.1007/s00018-021-03889-5$$n16$$p5953-5976$$tCellular and molecular life sciences$$v78$$x1420-9071$$y2021
000169806 909CO $$ooai:inrepo02.dkfz.de:169806$$pVDB
000169806 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4658b59d5b4e54b919fc63ab1213c78f$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000169806 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000169806 9130_ $$0G:(DE-HGF)POF3-316$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfections and cancer$$x0
000169806 9141_ $$y2021
000169806 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-02-03$$wger
000169806 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-02-03$$wger
000169806 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-02-03
000169806 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-02-03
000169806 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-02-03
000169806 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-02-03
000169806 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-03
000169806 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-02-03
000169806 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings$$d2021-02-03
000169806 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-03
000169806 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-02-03
000169806 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-02-03
000169806 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-02-03
000169806 9201_ $$0I:(DE-He78)F140-20160331$$kF140$$lF140 Zelluläre Polarität und virale Infektion$$x0
000169806 980__ $$ajournal
000169806 980__ $$aVDB
000169806 980__ $$aI:(DE-He78)F140-20160331
000169806 980__ $$aUNRESTRICTED